Anti-Human CD11a (Efalizumab)Anti-Human CD11a (Efalizumab)
Move your mouse over image or click to enlarge

Anti-Human CD11a (Efalizumab)

CD11a and CD18 are the Integrin alpha-L and beta-2 subunits that combine to form LFA-1, a glycoprotein and a member of the Integrin family. The Integrin alpha-L/beta-2 complex is a receptor for ICAM1, ICAM2, ICAM3, ICAM4 and F11R. LFA-1 participates in the immunological synapses between CD8+ T lymphocytes and antigen-presenting cells. Efalizumab binds to the CD11a subunit of LFA-1 and acts as an immunosuppressant by inhibiting lymphocyte activation and cell migration out of blood vessels into tissues. Anti-Human CD11a (Efalizumab) utilizes the same variable regions from the therapeutic antibody Efalizumab making it ideal for research projects.
Cat# Size Price Qty Buy
LT800-1mg 1.0 mg
£1,312.50
LT800-0.2mg 0.2 mg
£328.13
LT800-25ug 25 ug
£107.81

Additional Information

Property Value or Rating
Manufacturer Cat# LT800
Concentration ≥ 5.0 mg/ml
Formulation This recombinant monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (PBS) pH 7.2 - 7.4, 150 mM NaCl with no carrier protein, potassium, calcium or preservatives added.
Manufacturer Leinco Technologies Inc
Isotype IgG1 κ
Clone hu1124
Applications B, CyTOF®, ELISA, FA, FC, IHC
Antigen CD11a is expressed on all leukocytes.
Storage Functional grade biosimilar antibodies may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at -80°C. Avoid Repeated Freeze Thaw Cycles.
Protein CD11a

Related Documents